Twitter universal website tag code Twitter website tag code

[Skip to content]

Private hospital continually investing in advanced diagnostic and treatment technologies
Search our Site

Clinical Oncologist Katie Newbold, Private Clinic Treatment, Self Pay Patients

Dedicated GP referral service

Call Cromwell Direct to make a referral on

+44 (0)800 783 9229

More about Cromwell Direct

Make a referral

Refer a patient to us by telephone, fax or email

How to refer

Make an appointment

8am-8pm Monday to Friday
8am-2pm Saturday
Call our Contact Centre on

+44 (0)20 7460 5700

Contact Us

Dr Katie Newbold, Consultant Clinical Oncologist

Specialist Details
Full name

Dr Katie Newbold




Consultant Clinical Oncologist


Oncology - clinical (radiation)

Site specialisation

Head and neck cancer, thyroid cancer

Site specialisation 2
Clinical interests

Management of thyroid cancer, radioiodine and targeted therapies (tyrosine kinase inhibitors). Management of head and neck cancers using radiotherapy and chemotherapy.

Background Information

Dr Kate Newbold is a Consultant Clinical Oncologist specialising in the treatment of patients with cancer of the head, neck and thyroid 
Dr Newbold qualified from Bristol University in 1996, and completed general medical training in Bristol and Cheltenham. She completed her specialist training at The Royal Marsden and Guy's and St Thomas' in London. She undertook research at The Royal Marsden between 2003 and 2005, and was awarded an MD in 2007. 
Her research interests include functional imaging applied to the oncological management of head and neck cancer, dosimetric delivery of radioisotopes and novel systemic therapies in thyroid cancer.

Languages spoken


Regular Cromwell clinics


Clinic days

Mon: Tue: eveWed: Thurs: Fri: Sat:

Appointments telephone number

020 7042 1855

Additional Career Information
Year qualified


NHS hospitals

Royal Marsden

Research interests

New treatments for thyroid cancer. Advanced imaging techniques for head and neck cancer.

Key published papers

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.  N Engl J Med. 2015 Feb 12;372(7):621-30. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.  Clin Cancer Res. 2015 Aug 26. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHTstudy. Radiat Oncol. 2015 May 15;10(1):112. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Engl J Med. 2012 May 3;366(18):1674-85. Brain-Sparing Methods for IMRT of Head and Neck Cancer. PLoS One. 2015 Mar 17;10(3):e0120141


Media coverage

Our health professionals regularly contribute to hospital publications, as well as national newspaper articles and television coverage.